GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seres Therapeutics Inc (NAS:MCRB) » Definitions » Cyclically Adjusted Revenue per Share

Seres Therapeutics (Seres Therapeutics) Cyclically Adjusted Revenue per Share : $0.00 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Seres Therapeutics Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Seres Therapeutics's adjusted revenue per share for the three months ended in Dec. 2023 was $0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-04-28), Seres Therapeutics's current stock price is $0.825. Seres Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $0.00. Seres Therapeutics's Cyclically Adjusted PS Ratio of today is .

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Seres Therapeutics was 5.68. The lowest was 1.17. And the median was 2.74.


Seres Therapeutics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Seres Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seres Therapeutics Cyclically Adjusted Revenue per Share Chart

Seres Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Seres Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.87 0.85 -

Competitive Comparison of Seres Therapeutics's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Seres Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Seres Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seres Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Seres Therapeutics's Cyclically Adjusted PS Ratio falls into.



Seres Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Seres Therapeutics's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0/129.4194*129.4194
=0.000

Current CPI (Dec. 2023) = 129.4194.

Seres Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.000 99.695 0.000
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.069 100.470 0.089
201606 0.076 101.688 0.097
201609 0.323 101.861 0.410
201612 0.075 101.863 0.095
201703 0.075 102.862 0.094
201706 0.075 103.349 0.094
201709 0.568 104.136 0.706
201712 0.075 104.011 0.093
201803 0.098 105.290 0.120
201806 0.113 106.317 0.138
201809 0.222 106.507 0.270
201812 0.260 105.998 0.317
201903 0.178 107.251 0.215
201906 0.278 108.070 0.333
201909 0.101 108.329 0.121
201912 0.109 108.420 0.130
202003 0.116 108.902 0.138
202006 0.082 108.767 0.098
202009 0.017 109.815 0.020
202012 0.192 109.897 0.226
202103 0.062 111.754 0.072
202106 0.057 114.631 0.064
202109 1.335 115.734 1.493
202112 0.090 117.630 0.099
202203 0.016 121.301 0.017
202206 0.013 125.017 0.013
202209 0.028 125.227 0.029
202212 0.008 125.222 0.008
202303 -0.004 127.348 -0.004
202306 0.974 128.729 0.979
202309 0.002 129.860 0.002
202312 0.000 129.419 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Seres Therapeutics  (NAS:MCRB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Seres Therapeutics was 5.68. The lowest was 1.17. And the median was 2.74.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Seres Therapeutics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Seres Therapeutics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Seres Therapeutics (Seres Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
200 Sidney Street, 4th Floor, Cambridge, MA, USA, 02139
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
Executives
Paula Cloghessy officer: See Remarks C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Matthew R. Henn officer: Chief Scientific Officer C/O SERES THERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE MA 02139
Eric D. Shaff officer: CFO and EVP C/O SERES HEALTH, INC., 161 FIRST STREET, CAMBRIDGE MA 02472
Thomas Desrosier officer: See Remarks 65 HAYDEN AVENUE, LEXINGTON MA 02421
Moltke Lisa Von officer: See Remarks C/O SERESTHERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE MA 02139
Teresa L. Young officer: See Remarks C/O SERES THERAPEUTICS, INC., SUITE 1750, HOUSTON TX 77098
David S. Ege officer: See Remarks C/O SERES THERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE MA 02139
David Arkowitz officer: Chief Financial Officer C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Claire Fraser director C/O BECTON, DICKINSON AND COMPANY, FRANKLIN LAKES NJ 07465
Flagship Pioneering Fund Vii General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Pioneering Fund Vii, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Nutritional Health Ltp Fund, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Ventures Fund Iv, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Ventures Fund Iv General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Fund Iv-rx, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142

Seres Therapeutics (Seres Therapeutics) Headlines